FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant proteins of growth differentiation factor-15 (GDF15), and can be used in medicine for preventing or treating diabetes, obesity, dyslipidemia or metabolic syndrome. Disclosed are versions of GDF15, in the structure of which an N-terminal extension domain with SEQ ID NO: 3, 4 or 5. Core domain is a polypeptide derived from SEQ ID NO: 20, in which any one amino acid selected from the group consisting of amino acids in positions 15, 50, 58 and 97 in the amino acid sequence SEQ ID NO: 20 is replaced with another amino acid.
EFFECT: invention provides obtaining a variant of GDF15 with improved physiological activity and stability, as well as a long-acting GDF15 fusion protein.
28 cl, 13 dwg, 13 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION POLYPEPTIDE INCLUDING Fc REGION OF IMMUNOGLOBULIN AND GDF15 | 2020 |
|
RU2797520C2 |
| FUSION POLYPEPTIDE CONTAINING GDF15 AND POLYPEPTIDE REGION CAPABLE OF O-GLYCOSYLATION | 2020 |
|
RU2812049C1 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
